NEO100

Neonc Technologies, Inc. · Phase 2 active Small molecule

At a glance

Generic name	NEO100
Sponsor	Neonc Technologies, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis (PHASE1, PHASE2)
NEO100 and High-Grade Meningioma (PHASE2)
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma (PHASE1, PHASE2)
A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NEO100 CI brief — competitive landscape report
NEO100 updates RSS · CI watch RSS
Neonc Technologies, Inc. portfolio CI